STAT+: A former AI regulator, now in industry, says biopharma is reading FDA’s guidance wrong
By
Brittany Trang
Source
STATSTAT+: A former AI regulator, now in industry, says biopharma is reading FDA’s guidance wrongstatnews.comYou might also wanna read
Skeptical reader critiques AI CEOs' bioweapons warning to Congress as thinly veiled push for minimal regulation
A skeptical reader encounters a Fortune article about AI CEOs (from OpenAI, Anthropic, and Microsoft) warning Congress that AI makes bioweap
AI leaders unite in call for US regulations to prevent AI-aided bioweapon development
AI industry rivals including Anthropic's Dario Amodei, OpenAI's Sam Altman, and Microsoft's Mustafa Suleyman have united in an open letter t
AI regulation must shift from minimising risk to managing it, argue O'Donnell and White
Gus O'Donnell and Sharon White argue that outdated regulation poses as big a threat as the AI technologies it aims to govern. Using the exam

AI industry leaders unite to urge US lawmakers on bioweapon safeguards
AI industry rivals including Anthropic's Dario Amodei, OpenAI's Sam Altman, and Microsoft's Mustafa Suleyman have united in an open letter t

AI industry leaders unite to urge US lawmakers on bioweapon safeguards
AI industry rivals including Anthropic's Dario Amodei, OpenAI's Sam Altman, and Microsoft's Mustafa Suleyman have united in an open letter t
MIT researchers call for FDA oversight of unregulated AI tools used in US hospitals
MIT researchers published a viewpoint in The Lancet Digital Health highlighting that many AI tools used in clinical decision-making across U
How AI Will Transform Biopharma: The Sequence of Change Matters
Ben Liu, CEO of Formation Bio, argues that AI will transform the pharmaceutical industry unevenly and sequentially. Some parts of drug disco

Comments
Sign in to join the conversation.
No comments yet. Be the first.